Skip to main content
. 2017 Mar 16;19(6):897–900. doi: 10.1111/dom.12876

Figure 1.

Figure 1

Time course of A, changes in eGFR and B, incidence of renal‐related AEs with canagliflozin and glimepiride over 104 weeks. GLIM, glimepiride; CANA, canagliflozin; s.e., standard error. Panel A reprinted from American Diabetes Association, Diabetes Care , Copyright © 2015. Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association.